An observational cross-sectional study to determine clinical outcomes in adults with acute migraine using at least 4 doses of ubrogepant in real-world settings
Latest Information Update: 30 May 2022
Price :
$35 *
At a glance
- Drugs Ubrogepant (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms UNIVERSE STUDY
- 26 Apr 2022 Results of a subgroup analysis assessed the real-world effectiveness of ubrogepant for the acute treatment of migraine in patients who switched to ubrogepant due to the lack of efficacy of their prior acute treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 01 Oct 2021 New trial record
- 12 Sep 2021 Interim results (n=84) presented at The International Headache Congress - International headache Society with the European headache Federation joint congress 2021